Globus Medical earnings release, May 7, 2026

Globus Medical Inc (GMED) · Form 8-K, Item 2.02 · Filed · SEC filing

Globus Medical Reports First Quarter 2026 Results

AUDUBON, PA., May 7, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026.

First Quarter 2026:

• Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis.

• Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis.

• GAAP net income for the quarter was $124.3 million.

• GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%. Non-GAAP diluted EPS was $1.12, an increase of 64.7%.

“We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven by share gains and procedural volume strength in core spine, while Enabling Technologies delivered against its pipeline and continued to expand its customer base,” commented Keith Pfeil, President and Chief Executive Officer. “Disciplined execution on manufacturing and supply chain initiatives, as well as structural cost actions, coupled with operating leverage on higher volumes, drove margin expansion in excess of sales growth, which we expect to favorably impact full-year results. Our strategic priority remains centered on achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence system.”

“In the first quarter, US Spine continued to lead the way in growth for the organization, posting the third straight 10% growth quarter when compared to the same quarter of the prior year. This, paired with growth across all of our significant underlying businesses, drove record first quarter GAAP and non-GAAP net income and diluted earnings per share,” said Kyle Kline, Chief Financial Officer. “Nevro performed as expected as we continue to diligently work through the integration and adapt the business to Globus’ systems, processes, and metrics. Our total Company first quarter results represent an impressive beginning to 2026, reflecting the ongoing benefits of operating leverage, synergy realization, and financial discipline, positioning us well to deliver sustained earnings growth and value creation throughout the year.”

Worldwide net sales for the first quarter of 2026 were $759.9 million, an as-reported increase of 27.0% over the first quarter of 2025. U.S. net sales for the first quarter of 2026 increased by 25.0% compared to the first quarter of 2025. International net sales increased by 35.6% over the first quarter of 2025 on an as-reported basis and increased by 27.8% on a constant currency basis.

GAAP net income for the first quarter of 2026 was $124.3 million, an increase of 64.7% over the same period in the prior year. The increase in GAAP net income was primarily driven by higher sales of $161.7 million, with the sales from the acquisition of Nevro contributing $82.7 million. GAAP diluted EPS for the first quarter was $0.90, compared to $0.54 for the first quarter of 2025, an increase of 66.6%. Non-GAAP diluted EPS for the first quarter of 2026, which excludes, among other costs, amortization of intangibles, merger and acquisition-related costs, and restructuring-related costs, was $1.12, compared to $0.68 in the first quarter of 2025, an increase of 64.7%.

2026 Annual Guidance

The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50.

Conference Call Information

Globus Medical will hold a teleconference to discuss its 2026 first quarter results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news-events/events-webcasts.

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.

Non-GAAP Financial Measures... (truncated)come taxes and interest income and expense. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, legal and tax fees for legal entity reorganization and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.

In addition, for the period ended March 31, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non-recurring tax adjustments, and the tax effects of all of the foregoing adjustments. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present non-GAAP gross profit, which excludes the impacts of any inventory acquisition-related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends.

Additionally, for the period ended March 31, 2026 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates. We are also presenting base business sales and base Adjusted EBIDTA, excluding the contribution from the recently acquired Nevro Corp. (“Nevro”) and its subsidiaries. We believe these provide insight to how the Company is performing without the impact of our most recent acquisition.

Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP gross profit, free cash flow, constant currency net sales growth, base business sales, excluding the contribution from the recently acquired Nevro, and day-adjusted basis sales are not calculated in conformity with GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of these non-GAAP measures may differ from that of other companies and therefore may not be comparable. The tables included in this release reconcile the GAAP financial measures to the non-GAAP financial measures discussed above for the three months ended March 31, 2026.

We are unable to present a quantitative reconciliation of our expected fully diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of provision for litigation, amortization of intangibles, merger and acquisition-related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, certain income tax net benefits from non-recurring tax adjustments, gains and losses from strategic investments, and the tax effects of all of the foregoing adjustments. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Income.... (trunr Statements

Financial statements

Income Statement

Three Months Ended March 31, — (unaudited) (In thousands, except per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net sales759,854598,121
Cost of Sales and Operating expenses:Cost of sales (exclusive of amortization of intangibles)234,066195,397
Cost of Sales and Operating expenses:Research and development36,51033,062
Cost of Sales and Operating expenses:Selling, general and administrative297,775242,799
Cost of Sales and Operating expenses:Amortization of intangibles29,52628,802
Cost of Sales and Operating expenses:Acquisition-related costs6,3771,057
Cost of Sales and Operating expenses:Restructuring costs5,212
Cost of Sales and Operating expenses:Operating income/(loss)150,38897,004
Other income/(expense), netInterest income/(expense), net5,4341,681
Other income/(expense), netForeign currency transaction gain/(loss)-2,1134,270
Other income/(expense), netBargain purchase gain1,118
Other income/(expense), netOther income/(expense)2,247713
Other income/(expense), netTotal other income/(expense), net6,6866,664
Other income/(expense), netIncome/(loss) before income taxes157,074103,668
Other income/(expense), netIncome tax provision/(benefit)32,77228,206
Other income/(expense), netNet income/(loss)124,30275,462
Other comprehensive income/(loss), net of tax:Unrealized gain/(loss) on marketable securities-1,160315
Other comprehensive income/(loss), net of tax:Foreign currency translation gain/(loss)2184,379
Other comprehensive income/(loss), net of tax:Total other comprehensive income/(loss), net of tax-9424,694
Other comprehensive income/(loss), net of tax:Comprehensive income/(loss)123,36080,156
Earnings per share:Basic0.920.55
Earnings per share:Diluted0.90.54
Weighted average shares outstanding:Basic135,364136,757
Weighted average shares outstanding:Diluted138,191139,774

Income Statement

Three Months Ended March 31, — Non-GAAP Adjusted EBITDA Reconciliation Table: (In thousands, except percentages)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net income/(loss)124,30275,462
Interest (income)/expense, net-5,434-1,681
Provision for income taxes32,77228,206
Depreciation and amortization70,12166,074
EBITDA221,761168,061
Stock-based compensation expense12,61413,052
Provision for litigation, net134-1,287
Merger and acquisition-related costs (1)6,4411,106
Net (gain) loss from strategic investments-825-61
Non-cash acquisition-related foreign currency impacts-98-3,772
Restructuring costs6,387734
Bargain purchase gain-1,118
Adjusted EBITDA245,296177,833
Net income/(loss) as a percentage of net sales16.4%12.6%
Adjusted EBITDA as a percentage of net sales32.3%29.7%

Income Statement

Three Months Ended March 31, — Non-GAAP Gross Profit Reconciliation Table: (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net sales759,854598,121
Cost of sales (exclusive of amortization of intangibles)234,066195,397
Amortization of intangibles21,13122,208
Gross Profit504,657380,516
Amortization of inventory fair value step up49
Amortization of intangibles21,13122,208
Adjusted Gross Profit525,788402,773
Gross Profit % of Net Sales66.463.6
Adjusted Gross Profit % of Net Sales69.267.3

Income Statement

Three Months Ended March 31, — Non-GAAP Diluted Earnings Per Share Reconciliation Table: (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Diluted earnings per share, as reported0.90.54
Provision for litigation, net-0.01
Amortization of intangibles0.210.21
Merger and acquisition -related costs (1)0.050.01
Net (gain) loss from strategic investments-0.010
Non-cash acquisition-related foreign currency impacts-0.03
Restructuring costs0.050.01
Bargain purchase gain-0.01
Tax effect of adjusting items-0.07-0.04
Non-GAAP diluted earnings per share1.120.68

Balance Sheet

December 31, — (unaudited) (In thousands, except share and per share values)

March 31, – 2026December 31, – 2025
Cash and cash equivalents560,950526,156
Short-term marketable securities68,90131,087
Accounts receivable, net of allowances $40,933 and $33,434, respectively686,433678,938
Inventories772,602759,277
Prepaid expenses and other current assets60,22865,426
Income taxes receivable49,00664,727
Total current assets2,198,1202,125,611
Property and equipment, net557,139564,452
Operating lease right of use assets61,50763,786
Long-term marketable securities169,43771,819
Intangible assets, net720,845745,064
Goodwill1,438,7331,435,033
Other assets78,96478,781
Deferred income taxes214,810218,215
Total assets5,439,5555,302,761
Current liabilities:Accounts payable103,65898,852
Current liabilities:Accrued expenses313,431333,586
Current liabilities:Operating lease liabilities15,12114,738
Current liabilities:Income taxes payable3,0324,155
Current liabilities:Business acquisition liabilities20,87419,513
Current liabilities:Deferred revenue26,34727,655
Current liabilities:Total current liabilities482,463498,499
Current liabilities:Business acquisition liabilities, net of current portion79,44481,995
Current liabilities:Operating lease liabilities100,102103,918
Current liabilities:Deferred income taxes and other tax liabilities24,65823,756
Current liabilities:Other liabilities20,57621,343
Current liabilities:Total liabilities707,243729,511

Cash Flow

Three Months Ended March 31, — (unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net income124,30275,462
Adjustments to reconcile net income to net cash provided by operating activities:Bargain purchase gain-1,118
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization69,85665,653
Adjustments to reconcile net income to net cash provided by operating activities:Provision for excess and obsolete inventory4,9605,960
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of acquisition accounting fair value step up6,707
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation expense12,61713,206
Adjustments to reconcile net income to net cash provided by operating activities:Allowance for expected credit losses5,2773,206
Adjustments to reconcile net income to net cash provided by operating activities:Change in fair value of business acquisition liabilities6,352167
Adjustments to reconcile net income to net cash provided by operating activities:Change in deferred income taxes7,962509
Adjustments to reconcile net income to net cash provided by operating activities:(Gain)/loss on disposal of assets, net2,4492,613
Adjustments to reconcile net income to net cash provided by operating activities:Payment of business acquisition-related liabilities-2,273-2,012
Adjustments to reconcile net income to net cash provided by operating activities:Net (gain)/loss from foreign currency adjustment98-3,772
(Increase) decrease in:Accounts receivable-13,39922,603
(Increase) decrease in:Inventories-16,651-7,587
(Increase) decrease in:Prepaid expenses and other assets6,9424,534
Increase (decrease) in:Accounts payable5,082-899
Increase (decrease) in:Accrued expenses and other liabilities-24,668-28,658
Increase (decrease) in:Income taxes payable/receivable14,57619,608
Increase (decrease) in:Net cash provided by/(used in) operating activities202,364177,300
Cash flows from investing activities:Purchases of marketable securities-146,393-1,750
Cash flows from investing activities:Sales and maturities of marketable securities8,243174,238
Cash flows from investing activities:Purchases of property and equipment-39,615-36,103
Cash flows from investing activities:Acquisition of businesses, net of cash acquired and purchases of intangible and other assets-4,909-5,000
Cash flows from investing activities:Net cash provided by/(used in) investing activities-182,674131,385
Cash flows from financing activities:Payment of business acquisition-related liabilities-4,324-3,890
Cash flows from financing activities:Net proceeds from exercise of stock options25,96111,223
Cash flows from financing activities:Payments related to tax withholdings for share-based compensation-3,440-2,293
Cash flows from financing activities:Repurchase of common stock-190,451
Cash flows from financing activities:Repayment of senior convertible notes-449,985
Cash flows from financing activities:Net cash provided by/(used in) financing activities18,197-635,396
Cash flows from financing activities:Effect of foreign exchange rates on cash-3,0933,539
Cash flows from financing activities:Net increase/(decrease) in cash and cash equivalents34,794-323,172
Cash flows from financing activities:Cash and cash equivalents at beginning of period526,156784,438
Cash flows from financing activities:Cash and cash equivalents at end of period560,950461,266
Supplemental disclosures of cash flow information:Income taxes paid, net5,9917,199
Non-cash investing and financing activities:Accrued purchases of property and equipment10,51710,014

Cash Flow

Three Months Ended March 31, — Non-GAAP Free Cash Flow Reconciliation Table: (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net cash provided by operating activities202,364177,300
Purchases of property and equipment-39,615-36,103
Free cash flow162,749141,197
Full release

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Globus Medical earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.